Gabelli Funds LLC Sells 9,450 Shares of Zoetis Inc. $ZTS

Gabelli Funds LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 61,250 shares of the company’s stock after selling 9,450 shares during the period. Gabelli Funds LLC’s holdings in Zoetis were worth $7,706,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. RFG Advisory LLC grew its holdings in shares of Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares during the last quarter. YANKCOM Partnership grew its holdings in shares of Zoetis by 3.5% during the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares during the last quarter. Evergreen Capital Management LLC grew its holdings in shares of Zoetis by 3.3% during the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after purchasing an additional 85 shares during the last quarter. Beese Fulmer Investment Management Inc. grew its holdings in shares of Zoetis by 2.4% during the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares during the last quarter. Finally, Quest 10 Wealth Builders Inc. grew its holdings in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.9%

NYSE:ZTS opened at $79.64 on Thursday. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23. The business’s 50-day moving average price is $109.69 and its two-hundred day moving average price is $119.37. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a market capitalization of $33.39 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company posted $1.48 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZTS. UBS Group decreased their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Citigroup cut their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday. Stifel Nicolaus set a $105.00 price target on Zoetis in a research note on Friday, May 8th. JPMorgan Chase & Co. cut their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus target price of $134.75.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.